Literature DB >> 11405831

Clinical factors associated with progression of glaucomatous optic disc damage in treated patients.

G Tezel1, K D Siegmund, K Trinkaus, M B Wax, M A Kass, A E Kolker.   

Abstract

BACKGROUND: Reducing intraocular pressure (IOP) in glaucomatous eyes does not always prevent disease progression.
OBJECTIVE: To determine the clinical factors associated with progressive optic disc damage in glaucomatous eyes receiving treatment to reduce IOP.
METHODS: Baseline and follow-up optic disc photographs as well as demographic and clinical data were retrospectively studied in 186 eyes of 93 patients with primary open-angle glaucoma, and in 138 eyes of 69 patients with normal-pressure glaucoma. The patients with primary open-angle glaucoma were included in the study only if their treated IOPs during a follow-up period of 5 years were less than 21 mm Hg. The patients with normal-pressure glaucoma were included only if their IOPs were reduced by at least 20% during the follow-up period. The association of progressive optic disc damage with patient- and eye-specific characteristics was examined using multivariate analysis.
RESULTS: During the 5-year study period, 141 (43.5%) of the 324 eyes exhibited progressive optic disc damage defined by at least a 5% decrease in the neural rim area-to-disc area ratio. Using multivariate analysis, the following were found to be strongly associated with progressive neural rim damage: a baseline smaller neural rim area-disc area ratio (P<.001); a baseline larger zone beta area-disc area ratio (P =.04); a baseline larger parapapillary atrophy length-disc circumference ratio (P =.05); a diagnosis of normal-pressure glaucoma (P =.01); and combined medical and surgical treatment prior to the study period (P =.01).
CONCLUSIONS: Clinical factors other than IOP may be important indicators of subsequent progression of glaucomatous optic disc damage. Our findings suggest that eyes with advanced glaucomatous optic disc damage and normal-pressure glaucoma are more likely to progress despite receiving treatment to reduce IOP.

Entities:  

Mesh:

Year:  2001        PMID: 11405831     DOI: 10.1001/archopht.119.6.813

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  19 in total

1.  The path to open-angle glaucoma gene discovery: endophenotypic status of intraocular pressure, cup-to-disc ratio, and central corneal thickness.

Authors:  Jac Charlesworth; Patricia L Kramer; Tom Dyer; Victor Diego; John R Samples; Jamie E Craig; David A Mackey; Alex W Hewitt; John Blangero; Mary K Wirtz
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-17       Impact factor: 4.799

2.  Open angle glaucoma effects on preattentive visual search efficiency for flicker, motion displacement and orientation pop-out tasks.

Authors:  James Loughman; Peter Davison; Ian Flitcroft
Journal:  Br J Ophthalmol       Date:  2007-08-16       Impact factor: 4.638

3.  Gene expression changes in the retina after systemic administration of aldosterone.

Authors:  Aoi Ono; Kazuyuki Hirooka; Yuki Nakano; Eri Nitta; Akira Nishiyama; Akitaka Tsujikawa
Journal:  Jpn J Ophthalmol       Date:  2018-04-30       Impact factor: 2.447

Review 4.  Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences.

Authors:  Gülgün Tezel
Journal:  Prog Retin Eye Res       Date:  2006-09-07       Impact factor: 21.198

5.  Gene therapy in glaucoma-part I: Basic mechanisms and molecular genetics.

Authors:  Mohamed A E Soliman Mahdy
Journal:  Oman J Ophthalmol       Date:  2010-01

6.  Alterations in the morphology of lamina cribrosa pores in glaucomatous eyes.

Authors:  G Tezel; K Trinkaus; M B Wax
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

Review 7.  Neurobiology of glaucomatous optic neuropathy: diverse cellular events in neurodegeneration and neuroprotection.

Authors:  Martin B Wax; Gülgün Tezel
Journal:  Mol Neurobiol       Date:  2002-08       Impact factor: 5.590

8.  Immunomodulation as a Neuroprotective Strategy for Glaucoma Treatment.

Authors:  Mine Bariş; Gülgün Tezel
Journal:  Curr Ophthalmol Rep       Date:  2019-04-23

Review 9.  Molecular regulation of neuroinflammation in glaucoma: Current knowledge and the ongoing search for new treatment targets.

Authors:  Gülgün Tezel
Journal:  Prog Retin Eye Res       Date:  2021-08-01       Impact factor: 21.198

10.  A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits.

Authors:  Françoise Brignole-Baudouin; Nicolas Desbenoit; Gregory Hamm; Hong Liang; Jean-Pierre Both; Alain Brunelle; Isabelle Fournier; Vincent Guerineau; Raphael Legouffe; Jonathan Stauber; David Touboul; Maxence Wisztorski; Michel Salzet; Olivier Laprevote; Christophe Baudouin
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.